Bioavailability of Spermidine in Healthy Males
- Conditions
- Healthy Subjects
- Registration Number
- NCT06017219
- Lead Sponsor
- Chrysea Labs Lda
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- Male
- Target Recruitment
- 6
Inclusion Criteria:<br><br> - Able to give written informed consent.<br><br> - Male.<br><br> - Age between 18-70 years inclusive.<br><br> - BMI between =18.5 and =28 kg/m2.<br><br> - In general good health, as determined by the investigator.<br><br> - Agree to abstain from consuming alcohol, grapefruit, or grapefruit juice for 72<br> hours prior to visit 2 and visit 3.<br><br> - Adequate vein access for cannulation and multiple blood draws.<br><br> - Able to communicate well with the Investigator, to understand and comply with the<br> requirements of the study and be judged suitable for the study in the opinion of the<br> Investigator.<br><br> - Willing to consume the study product.<br><br>Exclusion Criteria:<br><br> - History of anaphylaxis,<br><br> - Documented hypersensitivity reaction or a clinically important reaction to any<br> dietary/food supplement or drug,<br><br> - Intolerance or sensitivity to study product ingredients
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cmax. To evaluate the pharmacokinetics of two different doses (20 mg and 40mg) of spermidine in healthy males;Tmax. To evaluate the pharmacokinetics of two different doses (20 mg and 40mg) of spermidine in healthy males;T 1/2. To evaluate the pharmacokinetics of two different doses (20 mg and 40mg) of spermidine in healthy males.;AUC. To evaluate the pharmacokinetics of two different doses (20 mg and 40mg) of spermidine in healthy males
- Secondary Outcome Measures
Name Time Method